Microsporidia are opportunistic pathogens causing localized and disseminated disease in immunocompromised and especially in AIDS patients. 1, 2 Although classically considered as parasites, taxonomy is under revision and genome molecular analyses have shown that microsporidia may be closely related to fungi. 3 Two main genera are recognized: Enterocytozoon spp., responsible for approximately 80-90% of the clinically symptomatic infections, which are mainly localized, and Encephalytoyzoon spp., responsible of approximately 10% of infections with a higher tendency to disseminate. 2 Localized infections affect the digestive tract more frequently (chronic diarrhoea or biliary tract involvement). Disseminated infection can involve the lungs and the central nervous system (CNS). 2 In the era preceding highly active antiretroviral therapy, microsporidia were an important cause of diarrhoea in AIDS patients; nowadays its incidence has decreased. 2 Infection in solid organ transplant recipients is rare, with some case reports and small series published. 4, 5 Only two cases of pulmonary infection have been reported in allogeneic haematopoietic SCT (allo-HSCT) recipients, both with fatal outcomes. 6, 7 Here we report the first case of an allo-HSCT recipient who survived disseminated microsporidiosis infection with gut, pulmonary and CNS involvement.
Case report
A 49-year-old woman was admitted for allo-HSCT from an unrelated donor HLA matched 9/10 (one allele mismatched at Cw) to treat Hodgkin's lymphoma (stage IIA, nodular sclerosis) diagnosed 20 months earlier. The initial treatment included doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) Â 3. This treatment was switched to a salvage regimen of ifosfamide, carboplatin and etoposide due to progression, but had to be interrupted after two cycles because of an anaphylactic reaction to etoposide, and was followed by three cycles of DHAP. An auto-HSCT was performed 16 months earlier with remission of the disease. Localized relapse was diagnosed 11 months earlier and treated with radiotherapy. A new relapse was diagnosed 7 months earlier and treated with seven rescue BACOPP chemotherapy cycles (bleomycin, doxorubicin, CY, vincristine, procarbazine and prednisone). An allogenic, T-celldepleted, HSCT with reduced-intensity conditioning including fludarabine, melphalan and anti-lymhocytes serum was performed followed by T-cell addback of 5 Â 10 5 CD3 þ cells per kg. The patient experienced several complications including a Staphylococcus epidermidis implantable catheter-related infection treated with vancomycin and catheter ablation, a probable pulmonary fungal infection treated with voriconazole, CMV reactivation treated with ganciclovir, and hepatic grade II GVHD treated with CYA and methylprednisolone. All these complications were resolved, but the patient remained agranulocytopenic with sporadic fever spikes. Two months after allo-HSCT, still with persistent neutropenia while being treated with teicoplanin, meropenem, ganciclovir, atovaquone and voriconazole, the patient developed fever, diarrhoea, dyspnoea and confusion, followed by symptoms suggestive of meningeal involvement. A cerebral computerized tomography (CT) scan was unremarkable. A pulmonary CT scan was non-specific, with interstitial infiltrates. Bronchoalveolar lavage (BAL) revealed 90 cells per ml with a mononuclear predominance. Oral albendazole was initiated at 400 mg b.i.d. and increased to 400 mg t.i.d. To promote immune reconstitution, the patient received donor lymphocyte infusions (DLI; 1 Â 10 6 CD3 per kg at diagnosis and 5 Â 10 6 CD3 per kg 1 week later). Neurological recovery was complete after 3 weeks of therapy. Only diarrhoea persisted due to progressive GVHD that ultimately progressed to grade IV acute GVHD (gut þ þ þ , skin þ þ þ and liver þ þ ) and was treated by immunosuppression with methylprednisolone, tacrolimus and mycophenolate mofetil. Microsporidia were still found in the blood for 2 weeks after the specific treatment was started. The patient was finally discharged 5 months after allo-HSCT on oral albendazole 400 mg twice a week. Although the patient remained severely immunocompromised, and developed several other complications, including a relapse of gut GVHD and probable aspergillosis, microsporidia were never found again in stools, BAL or blood. Symptoms suggestive of CNS involvement never recurred. Unfortunately the GVHD ultimately progressed, with further complications including an infection of the patient's central venous access device, and the patient died 8 months after allo-HSCT, with negative blood, BAL and stool samples, and no signs suggestive of a relapse of microsporidiosis. Permission for a post-mortem examination was declined by the family.
Discussion
Microsporidiosis is an uncommon infection in transplant recipients, thus rarely considered in the differential diagnosis of infections in these patients. Diagnosis and treatment of this disease are difficult for several reasons. Clinical manifestations, including fever and diarrhoea are non-specific. Moreover, special stains such as Gramchromotrope 8 are needed to enhance microorganism detection, although fungal stains, such as fluorescence staining, can be useful, as shown in this case. 9 Although serologic tests might be considered for the diagnosis, antibody responses are impaired in severely immunocompromised patients. Moreover the specificity of these assays remains unknown. Molecular biology, including PCR and sequencing, is required to establish the genus level and species. 1 Immune reconstitution is crucial to control microsporidia infections. Albendazole is active against microsporidia, but only against organisms of the genus Encephalitozoon. 2 An i.v. formulation is not available, which complicates treatment of severely immunocompromised patients, especially those with CNS involvement, and those with diarrhoea (in this case related to gut GVHD), potently leading to reduced absorption of the drug. Fumagillin has shown activity against both Enterocytozoon and Encephalitozoon in HIV-infected patients with microsporidiarelated diarrhoea. 10 However, its myelotoxicity makes it difficult to use in allo-HSCT recipients. Molina et al. 10 reported neutropenia (o750 neutrophils per mm 3 ) in 33% and thrombocytopenia (o50 000 platelets per mm 3 ) in 33% of HIV patients receiving fumagillin, against 0% in the placebo group.
After E. cuniculi was identified, and given the response to albendazole, fumagillin was not considered. Neither dose nor treatment duration is clearly established in this clinical situation. Given the intense immunosuppressive maintenance therapy of our patient, it appeared reasonable to continue suppressive treatment until immunosuppression could be diminished. For the initial treatment, 800-1200 mg albendazole per day is recommended, 11 but this may cause liver and BM toxicities as well as neurological side effects. 11, 12 Albendazole penetrates blood-brain barrier, with concentrations in CSF reaching 50% of that found in plasma. 12 Once the microorganism was no longer detected, we gave maintenance treatment of 400 mg albendazole twice a week, and the patient remained free of disease. DLI is considered as an adjuvant therapy to increase immune reconstitution following haematopoietic SCT. 13 Our patient therefore received low doses of DLI. The resulting accelerated immune recovery may have helped to control the disseminated microsporidiosis in combination with albendazole. Unfortunately, DLI increases the risk of GVHD, which may be severe as shown by this case.
This case is extremely unusual because of the rarity of this disease among allo-HSCT recipients and its outcome. Indeed, only two cases have been previously reported. 6, 7 Both previous cases had pulmonary presentations and were diagnosed post mortem. Our case is the first case of disseminated microsporidiosis with neurological involvement after allo-HSCT and, moreover, with a favourable outcome. A comparison of published cases can be seen in Table 1 .
We recommend that invasive microsporidiosis should be considered in the differential diagnosis of allo-HSCT recipients with systemic illness, including diarrhoea, Table 1 Characteristics of the three published cases of microsporidiosis in allo-HSCT recipients Letter to the Editor pulmonary symptoms and meningeal involvement, especially when the patients receiving broad-spectrum antimicrobial treatment. Treatment should be based on identification of the species using specific stains and molecular techniques such as PCR and sequencing.
